Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | MLYCD | O95822 | 5/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7595533 | 0.88 | NOTUM (0.47) | NOTUMCA12CA1CA2CA9 | |
| SCHEMBL3070779 | 0.84 | NOTUM (0.47) | NOTUMCA12CA1CA2CA9 | |
| SCHEMBL20522076 | 0.83 | NOTUM (0.45) | NOTUMCES1CA12CA1CA2 | |
| SCHEMBL1071393 | 0.81 | NOTUM (0.58) | NOTUMCA12CA1CA2CA9 | |
| SCHEMBL5093115 | 0.81 | NOTUM (0.42) | NOTUMCA12CA1CA2CA9 | |
| SCHEMBL23412089 | 0.81 | NOTUM (0.58) | NOTUMACHECA12CA1CA2 | |
| SCHEMBL22926373 | 0.81 | NOTUM (0.43) | NOTUMCA12CA1CA2CA9 | |
| SCHEMBL29903445 | 0.81 | NOTUM (0.58) | NOTUMACHECA12CA1CA2 | |
| SCHEMBL3010098 | 0.81 | NOTUM (0.71) | NOTUMCA12CA1CA2CA9 | |
| SCHEMBL5094521 | 0.80 | NOTUM (0.41) | NOTUMCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117720468-A | Active probe for screening target proteins interfering colorectal cancer stem cells | 南开大学 | 2024-03-19 | — | — | CN | claimed |
| CN-117720468-A | Active probe for screening target proteins interfering colorectal cancer stem cells | 南开大学 | 2024-03-19 | — | — | CN | disclosed |
| EP-2215049-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2019-06-12 | — | — | EP | disclosed |
| US-8247401-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
| EP-2215049-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | Merck Sharp & Dohme Corp. (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009058298-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK & CO., INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | NOTUM 4636/4885ACHE 1040/4885CES1 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.